In ancient Rome the medicine of the first two centuries of the Christian era was dominated by the writings of Celsus, Dioscorides and Galen. But with the death of Galen in AD 201 original and experimental medical enquiry can be said to have ceased for over 1200 years. During this long interregnum learning continued in the Muslim West, and Europe, in what were our Dark Ages, learnt what little medicine it did learn from Latin translations of the huge, unwieldy Canon of Ibn Sina (AD 980-1037), the 'Prince of Physicians', known in the Latin West as Avicenna. It learnt its materia medica from the Grabadin medicinarum particularum, attributed to Mesue the Younger (d.c 1015).
In England, medicine, before the Norman Conquest of 1066, was in the hands of the Saxon leeches and the 'wise women' of the towns and villages. Matters were, however, better organized in the medieval Muslim countries where the office of the hisba was established in the early part of the 9th century for the safe keeping ofthe public morality. The functions of the hisba gradually expanded to embrace medicine and regulations were ultimately made concerning the work of the physicians and many of their associates, including the syrup makers (who also prepared medicines). Levey1 shows that these early Muslim regulations were stringent, for the syrup-makers could have their wares inspected 'at any time without warning after their shops are closed for the night'.
In the West the Dark Ages were broken by little except the establishment and gradual growth of the school of medicine which arose in the Italian city of Salerno. By the 10th century this famous school was enjoying a wide and venerable reputation and Clifford Allbutt2, describing the hospitals of Salerno at that time, says: 'there were inspectors of the drug-shops, as also for the public health, and against contagion'. These then, in the Muslim countries ofthe East, and in the West at Salerno, are the first clear evidences of a drug regulatory systemand they were much concerned with ensuring that the customer got from the apothecary what he paid for. The example may have led to attempts to regulate the practice of medicine itself and in 1140, Roger II, King of the Two Sicilies, promulgated the first law known in Europe for the regulation of medical practice. Roger's grandson, the German Emperor Frederick II, also issued laws between 1231 and 1241 supervising the art of the physician and the work of the apothecary.
Penn3 has reported that the earliest written code of quality control in Britain seems to be the Ordinances of the Gild of Pepperers of Soper Lane in 1316. The Pepperers in the 12th century took over the distribution of imported spices and herbs used as medicines and their experience is one of the clearer landmarks in the control of medicines in Britain before the Renaissance.
The Renaissance and its effects Throughout the length of the Middle Ages learning in almost the whole of Europe acknowledged theology as its master but, from about 1450, a number of events acted together to break the old mould. These several events, including the fall of Byzantium to the Turks in 1453, precipitated the Renaissance. The flight of the Byzantine scholars with their precious and relatively uncorrupted copies of the classic Greek texts proved to be one of the chief means of the re-awakening of Western medicine. Amongst those who consulted these fresh, newly available texts was Thomas Linacre (1460-1524) who travelled to Italy and is said to have been the first Englishman to have fully understood Aristotle and Galen in Greek. Late in his life, Linacre, in 1518, obtained by petition to Henry VIII the charter which established the Company of Physicians. In 1551 this body became the Royal College of Physicians of London. In 1540, by means of one of the earliest English statutes on the control of drugs (32 Hen. VIII c. 40: For physicians and their privileges), the physicians were empowered to appoint 4 inspectors of apothecaries' wares and destroy defective stock.
The College now known as the Royal College of Physicians and Surgeons of Glasgow was founded in 1599 by means of a charter granted by James VI of Scotland to Maister Peter Lowe, a surgeon, then aged about 50, who was probably a native of Errol in Perthshire. This charter gave Lowe and his assistant and their successors power to examine those who wanted to be surgeons and restrict the practice of medicine to those with the testimonial of a 'famous University where medicine is taught'. Its extensive provisions were unprecedented in the British Isles and included the supervision ofthe sale ofdrugs and poisons. James, after his removal from Scotland, was also instrumental in the establishment of the Society of Apothecaries. At this date there were no general practitioners of medicine as we now know them. The Apothecaries grew from within the Guild of Grocers but were not freed from it until 1617 (the year after Shakespeare's death) when James I and VI set the apothecaries apart from the grocers and, by charter, established them as 'The Worshipful Society of the Art and Mistery of Apothecaries'. In their turn some of the general practitioners arose from the Apothecaries who, in 1703, finally established their right to give medical advice as well as compound and sell remedies.
The Renaissance also saw the development of herbals of increasing volume and extent and these, together with the growth of the first official pharmacopoeias, served to codify the knowledge of drugs and protect their quality. The pharmacopoeias provided instructions for the compounding of medicines and they were, in function, quite unlike the descriptive herbals. The first pharmacopoeia to receive authorized publication and to be given official status appears to be the 1546 posthumous edition of the ... dispensatorium pharmacopolarum ofthe young and brilliant Valerius Cordus (1515-1544). The apothecaries of Nuremberg were required to make their preparations in accordance with this innovative and important book. There had been earlier town pharmacopoeias and these included the Venetian Luminare majus of 1496 and the Florentine Nuovo receptario ... of 1498. London had its first town pharmacopoeia quite late: the College of Physicians issued the Pharmacopoeia Londinensis in its first, very inaccurate, edition on 7 May 1618 and its second, corrected, edition on 7 December 1618. The London Pharmacopoeia had further editions in 1650 and 1677.
These editions contained some useful substances, including cinchona bark, digitalis and Irish whisky (but the 17th century had no idea how to use digitalis); they also contained a miscellany of filth including cast-off snake's skin, scorpions, swallow's nests, woodlice, and the triangular Wormian bone from the juncture of the sagittal and lambdoid sutures of the skull of an executed criminal.
The 1618 versions of the London Pharmacopoeia appeared at very much the same time as the Authorised Bible of 1611 and the death of Shakespeare in 1616. Despite their curious contents, showing the primitive state ofthe therapeutics ofthe day, they were printed a staggering 84 years after the Renaissance masterpiece, the De humani corporis fabricia libri septem of Andreas Vesalius (1514-1564) had made, upon its publication in 1543, what was virtually a modern science out of observational anatomy.
The beginnings of modern medicine Only slowly were the means oftherapeutics cleansed. A landmark was the first, brilliant published work of William Heberden (1710-1801) whose An essay on mithridatium and theriaca of 1745 did the subject a great deal of good by ridiculing its superstition and polypharmacy. The beginnings of clinical pharmacology and modern immunology can be dated from the appearance in Birmingham in 1785 of An account of the foxglove, and some of its medical uses ... by William Withering (1741-1799) and the 1798 pamphlet, An inquiry into the causes and effects ofthe variolae vaccinae ... of Edward Jenner (1749-1823) of Gloucestershire. Withering's account of digitalis, which provides the first scientific monograph on one drug in the literature, has been reviewed elsewhere.4
The discoveries of Withering and Jenner are really part of the small cluster of events which, almost exactly 200 years ago, marked the beginnings of modern medicine.
The pastoral world that Withering and Jenner knew was vastly changed by the later phases of the Industrial Revolution. The associated population increase led to a growing demand for medical care and the new situation showed itself in the Apothecaries Act of 1815. This Act so strengthened the Society of Apothecaries that it became responsible for the standard of medical practice throughout the country. Nevertheless, it was not until the process of medical reform was almost completed by the Medical Act of 1858 that the apothecaries who practised medicine were finally able to leave their shops and become general practitioners, akin to those of today. The mid 19th century apothecaries whose interests remained in pharmacy then joined forces with the better chemists and druggists of the day to found, in 1841, The Pharmaceutical Society of Great Britain.
The main groups of drugs of the early 19th century were the alkaloids and glycosides; the early inhalational anaesthetics followed in the middle years of the century and the early analgesics and barbiturates represented the discoveries of the later part ofthe century. The discovery of drugs ofthis type encouraged the growth of a pharmaceutical industry employing medicinal chemists and biological scientists who replaced the herbalists and apothecaries of the previous generations. Control of this growing pharmaceutical industry and some of its novel products and, where possible, of the diseases against which they were used, were gradually seen to be necessary.
Whilst the pharmacopoeia contained many botanical substances adulteration remained a problem. The development of chemical, physical and microscopical methods of testing drugs provided a basis for the Adulteration Act of 1860, although this applied only to foodstuffs and drinks. In 1872 it was extended to drugs and, by incorporating the Pharmacy Act of 1868, provided a short period of legal recognition for the British Pharmacopoeia. There was an Adulteration of Food and Drugs Act in 1872 and a Sale of Food and Drugs Act in 1875 -but the latter did not recognize the BP, which ceased to be a legal standard. The concerns of these Acts with product quality were supported not only by the growing strength of the Pharmaceutical Society of Great Britain but also by the developing technology, as exemplified by the founding of the Society of Public Analysts in 1874.
Control over the sale of poisons had long been recognized as being necessary when the Arsenic Act became law in 1851. This Act required details of the sale of arsenic to be recorded in a register. The first professional register ofthose qualified to sell poisons was established by the Pharmacy Act of 1852 but it was not until the Pharmacy Act of 1868 that any real attempt was made to control the labelling and retailing of poisons. The Poisons and Pharmacy Act of 1908 amended the earlier legislation but it was not until the Defence of the Realm (Consolidation) Regulations of 1917, during World War I, that the availability of drugs as potent as morphine, cocaine and barbitone was limited to supply on a medical prescription.
The first British Pharmacopoeia was of 1864. Its contents have been discussed elsewhere656 but it is striking to think that up to 1910 scientific medicine recognized as specific remedies only quinine, the alkaloid from cinchona which could eradicate certain malarial parasites; emetine, the alkaloid from ipecacuanha, which could eliminate the protozoal organisms ofamoebic dysentery; and mercury, which sometimes killed the spirochaete of syphilis before the syphilitic.
The modern era The chemotherapeutic revolution had its beginnings in the studies of Paul Ehrlich (1854-1915) at the turn ofthe century. Ehrlich's compound number 606 of his arsenical series was shown to be highly active in vivo against Treponema pallidum and in 1911, just before World War I, this drug was introduced, as 'Salvarsan', for the treatment of syphilis. The vitally important discovery of penicillin by Sir Alexander Fleming (1881-1955) took place in 1928 but, as is well known, the classical papers reporting the isolation and first clinical exploitation of the remarkable antibiotic had to await the World War II years of 1940 and 1941. A cascade of antibiotics and antimicrobial agents followed but we should remember how recent is our experience with the new agents of therapeutics. To take but a few examples: BCG was first used as a prophylactic in children in 1921; the discovery of insulin was reported in 1922; digoxin was isolated in 1930; and prontosil red, the first ofthe sulphonamide drugs, was used in 1935. Streptomycin was a wartime drugits key date of discovery being 1944. Vitamin B12 was first shown effective in pernicious anaemia after the war, in 1948. Pronethalol and then propranolol, the lead drugs of the adrenergic betablocking agents were of 1962. Cimetidine, the H2receptor blocker arising from equally brilliant use of receptor theory, came a decade later, its key reports being in 1972.
The modern concepts of the control of drug safety in Britain derive from the Therapeutic Substances Act of 1925. In the history of this subject this Act is of vital importance. There was a Pharmacy and Poisons Act of 1933 but this served mainly to establish the pharmacists as a self-governing profession. It was found that highly toxic impurities in drugs such as 'Salvarsan' (arsphenamine) could be detected only by biological testing. The standardization of vaccines and immunizing agents raised further complexities as the purity and potency of these substances could not be tested by chemical means. The Therapeutic Substances Act regulated the manufacture and sale of substances requiring biological testing. It relied heavily on a licensing system and an inspectorate providing for in-process control and careful batch-bybatch record keeping. The work of this inspectorate in providing for drug safety has seldom received adequate recognitionand some of the concepts underlying this Act remain important today as we begin to consider the pan-European registration of drugs throughout the EEC. Historically, the growing requirements and controls of the Therapeutic Substances Act were consolidated and revised in 1956 -but the Act remained concerned largely with drug safety.
The Venereal Disease Act of 1917 and the Cancer Act of 1939 aimed to prevent fraudulent claims of efficacy in these conditions of great public interest and importance but there was otherwise little control over drug efficacy or safety, apart from the Therapeutic Substances Act, as late as 1960 -and by this time many of the post-war agents of therapeutics were already known.
One of the strangest quirks of medical history makes this so: the British Medical Association had investigated 'secret remedies' in 1909 and 1912 and there had been a Select Committee on Patent Medicines in 1914. The report of this Select Committee has been reviewed elsewhere5'6, but its proposals startlingly foreshadow many ofthe eventual provisions of the Medicines Act, 1968 -and it is this Act which now, with the EEC Directives, controls drug registration in this country. The quirk of history is that, by mischance, the report of the Select Committee was ordered to be printed on 4 August 1914 -and this was the very day on which Britain, beginning World War I, declared war upon Germany.
Although the Select Committee of 1914 was largely concerned with proprietary medicines it did, in its report, envisage enforcement of the relevant law as being a Ministerial responsibility; it also recommended that there should be a full but confidential disclosure of the ingredients of these medicines to the competent authority. Most importantly, the Select Committee recommended the establishment of a 'special court or Commission ... with power to permit or to prohibit in the public interest ... the sale and advertisement of any patent, secret or proprietary remedy .. .'
Thus, but for the outbreak of World War I, a Medicines Commission and formal drug regulatory body might well have existed in Britain before most of the instruments of modern therapeutics were in place. If this control had been extended, as experience was gathered, to the marketing of new drugs, then some of the iatrogenic hazards of the last 25 years might well have been lessened or prevented. One can only speculate on the possibility that the thalidomide disaster might have been averted if World War I had not broken out just when it did.
In the event the recommendations of the Select Committee of 1914 were never implemented and between 1959 and 1962 the thalidomide tragedy produced an estimated 10 000 deformed children in those countries in which the drug was taken by women in the early stages of pregnancy. Following the disaster, in a debate in Parliament on 8 May 1963, the responsible Minister, Kenneth Robinson, said: 'I come to my last main topic which is the control and safety of drugs. This is of course a subject which was thrust to the fore both in this House and in the public press a year or so ago as a result of the thalidomide tragedy. The House and the public suddenly woke up to the fact that any drug manufacturer could market any product, however inadequately tested, however dangerous, without having to satisfy any independent body as to its efficacy and safety and the public was almost uniquely unprotected in this respect.'
After thalidomide, on the advice of a committee under Lord Cohen of Birkenhead, a Committee on Safety of Drugs was established by the Health Ministers to deal, on a voluntary basis, with the problem of drug regulation until legislation could be enacted. The Committee operated under the chairmanship of Sir Derrick Dunlop, whose personal contribution was immense. It was established in June 1963 and on 1 January 1964, began to assess drugs in order to 'advise whether a new drug should be submitted for clinical trial; to advise whether a drug should be released for marketing; and to study adverse reactions to drugs already in use. ' It should be noted that the Committee was not directly concerned with drug efficacy. In 1964 it established the yellow card reporting scheme for the recording of suspected adverse drug reactions. It operated until, on 1 September 1971, the 'first appointed day', the Dunlop Committee ceased to function and the Committee on Safety of Medicines began, in implementation of the Medicines Act 1968, to advise the Licensing Authority on the safety, efficacy and quality of those medicinal products on which advice was needed.
A somewhat similar set ofevents, though much less marked by thalidomide, occurred in the USA. A Food and Drugs Act became law in 1906. After the deaths of over 100 people who had used an elixir of sulphonilamide containing the toxic solvent, diethylene glycol, the original Act was replaced by the Federal Food, Drug and Cosmetic Act of 1943. In 1951 an Amendment required the regulation of prescription drugs. In 1962 the Kefauver-Harris Amendment introduced a requirement for the premarketing submission ofboth safety and efficacy data to the Food and Drugs Administration.
In Europe the Treaty of Rome in 1957 marked the formation ofthe European Economic Community, the EEC. In 1975 this body introduced the Committee for Proprietary Medicinal Products, the CPMP, which provides a forum for considering marketing authorizations on a Community-wide basis. Current speculation centres upon the possible establishment of an EEC-wide drug regulatory body which (at great cost to national sovereignty) might supplement or displace the presently established national drug regulatory agencies. A global view ofthe development of drug regulation to its present point has been provided by Professor Sir Abraham Goldberg7, recently Chairman of the Committee on Safety of Medicines.
That Committee has frequently reiterated the advice of its predecessor, the Committee on Safety of Drugs, that 'no drug which is pharmacologically effective is without hazard ... Furthermore, not all hazards can be known before a drug is marketed ... Hence the importance ofpost-marketing surveillance with all newly-introduced drugs intended for widespread, long-term clinical use. The current attempts to expand and improve the presently available means of post-marketing surveillance have their historical roots in the perennial human need for safe and effective medicines of adequate quality.
Conclusion
Any historical study is likely to emphasize how comparatively short our experience of integrated drug regulatory practice has been. Attempts to regulate the quality of medicines reach back to the Middle Ages. The emphasis in most ofthose early attempts was on the prevention of fraud.
As the herbal pharmacopoeia disappeared and both potent plant principles and synthesized new drugs were increasingly provided in the 19th century, the emphasis swung towards the control of drug purity and the implication of drug quality on the safety of medicines.
It is perhaps startling that the simultaneous control of the quality, safety and efficacy of medicines is, in historical terms, a very recent achievement indeed. This integrated type of control still provides considerable difficulties and it is now recognized that effective post-marketing surveillance is essential with most new drugs intended for widespread, long term use. The products ofbiotechnology may well challenge even further our ability to regulate effectively the instruments of therapeuticsand changes in drug regulatory control and adverse event monitoring9 are of ever increasing relevance to the work of the prescribing clinician.
